Based on these results, in December 2020 the FDA approved osimertinib for adjuvant treatment of surgically resected stage IB–IIIA NSCLC with deletions in exon 19 (Ex19del) or the exon 21 p.L858R mutation in EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.